SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-23-000055
Filing Date
2023-05-11
Accepted
2023-05-11 16:07:29
Documents
15
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20230511.htm   iXBRL 8-K 38561
2 EX-99.1 pressreleaseq1march2023.htm EX-99.1 71526
7 newlogo_09072021a.jpg GRAPHIC 17737
  Complete submission text file 0001599298-23-000055.txt   314651

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20230511.xsd EX-101.SCH 2159
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20230511_def.xml EX-101.DEF 15283
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20230511_lab.xml EX-101.LAB 29621
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20230511_pre.xml EX-101.PRE 15940
9 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20230511_htm.xml XML 11117
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 23910999
SIC: 2834 Pharmaceutical Preparations